LLS Investing in Cures
The Leukemia & Lymphoma Society is at
the center of the Food & Drug Administration's (FDA) innovative decision to
allow a nonprofit organization to lead its own clinical trial. The
target: acute myeloid leukemia (AML). It is the deadliest form of
leukemia and has not seen a new treatment option in more than 40 years.
LLS Investing in Patients
LLS is dedicating more than $125 million to the Beat AML initiative, which is focused on creating new treatment options for
AML patients. LLS is harnessing the efforts of geneticists,
pharmaceutical companies, government agencies and healthcare facilities in this
revolutionary approach to creating new therapies.
LLS Investing in North Texas
Dr. Robert Collins, Jr., a member of the North Texas LLS Medical
Advisory Board and LLS-funded researcher, has been charged with the task of
leading the ONLY Beat AML trial in the south at UT Southwestern Medical Center
Harold C. Simmons Comprehensive Cancer Center. Dr. Collins is currently
accepting newly diagnosed AML patients as part of the Beat AML Master Trial.
Click here to
learn more.
Hear More From Dr. Collins
Intrigued? You can hear more about the Beat AML trial from
Dr. Collins at the FREE
North Texas Cancer Expo on
Saturday, September 16th. Registration for this session is limited and
expected to fill quickly.
Click on the image below to hear Dr. Collins talk about
the Master Trial
